Literature DB >> 20084049

PharmGKB: very important pharmacogene--HMGCR.

Marisa Wong Medina1, Katrin Sangkuhl, Teri E Klein, Russ B Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 20084049      PMCID： PMC3098759          DOI： 10.1097/FPC.0b013e328336c81b

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  18 in total

1.  Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays.

Authors:  Jason M Johnson; John Castle; Philip Garrett-Engele; Zhengyan Kan; Patrick M Loerch; Christopher D Armour; Ralph Santos; Eric E Schadt; Roland Stoughton; Daniel D Shoemaker
Journal:  Science       Date:  2003-12-19       Impact factor: 47.728

2.  Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort.

Authors:  John F Thompson; Craig L Hyde; Linda S Wood; Sara A Paciga; David A Hinds; David R Cox; G Kees Hovingh; John J P Kastelein
Journal:  Circ Cardiovasc Genet       Date:  2009-02-12

3.  A combination of proatherogenic single-nucleotide polymorphisms is associated with increased risk of coronary artery disease and myocardial infarction in Asian Indians.

Authors:  Aruna Poduri; Madhu Khullar; Ajay Bahl; Yash Paul Sharma; Kewal K Talwar
Journal:  DNA Cell Biol       Date:  2009-09       Impact factor: 3.311

4.  Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.

Authors:  Ralph Burkhardt; Eimear E Kenny; Jennifer K Lowe; Andrew Birkeland; Rebecca Josowitz; Martha Noel; Jacqueline Salit; Julian B Maller; Itsik Pe'er; Mark J Daly; David Altshuler; Markus Stoffel; Jeffrey M Friedman; Jan L Breslow
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-09-18       Impact factor: 8.311

5.  A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study.

Authors:  Louise A Donnelly; Alex S F Doney; Jennifer Dannfald; Adrian L Whitley; Chim C Lang; Andrew D Morris; Peter T Donnan; Colin N A Palmer
Journal:  Pharmacogenet Genomics       Date:  2008-12       Impact factor: 2.089

6.  Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment.

Authors:  Ronald M Krauss; Lara M Mangravite; Joshua D Smith; Marisa W Medina; Dai Wang; Xiuqing Guo; Mark J Rieder; Joel A Simon; Steven B Hulley; David Waters; Mohammed Saad; Paul T Williams; Kent D Taylor; Huiying Yang; Deborah A Nickerson; Jerome I Rotter
Journal:  Circulation       Date:  2008-03-10       Impact factor: 29.690

7.  Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome.

Authors:  Ning Xu; Kent D Taylor; Ricardo Azziz; Mark O Goodarzi
Journal:  Fertil Steril       Date:  2009-03-26       Impact factor: 7.329

8.  Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin.

Authors:  Marisa Wong Medina; Feng Gao; Weiming Ruan; Jerome I Rotter; Ronald M Krauss
Journal:  Circulation       Date:  2008-06-16       Impact factor: 29.690

9.  Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.

Authors:  Eliana Polisecki; Hind Muallem; Nobuyo Maeda; Inga Peter; Michele Robertson; Alex D McMahon; Ian Ford; Christopher Packard; James Shepherd; J Wouter Jukema; Rudi G J Westendorp; Anton J M de Craen; Brendan M Buckley; Jose M Ordovas; Ernst J Schaefer
Journal:  Atherosclerosis       Date:  2008-02-07       Impact factor: 5.162

10.  The HMG-CoA reductase gene and lipid and lipoprotein levels: the multi-ethnic study of atherosclerosis.

Authors:  Yi-Chun Chen; Yii-Der I Chen; Xiaohui Li; Wendy Post; David Herrington; Joseph F Polak; Jerome I Rotter; Kent D Taylor
Journal:  Lipids       Date:  2009-06-25       Impact factor: 1.880
View more
  4 in total

1.  Pharmacogenomics and bioinformatics: PharmGKB.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

2.  Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.

Authors:  Najmeh Ahangari; Mohammad Doosti; Majid Ghayour Mobarhan; Amirhossein Sahebkar; Gordon A Ferns; Alireza Pasdar
Journal:  Ann Med       Date:  2020-08-24       Impact factor: 4.709

Review 3.  A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson's Disease.

Authors:  Anna Pierzchlińska; Marek Droździk; Monika Białecka
Journal:  Int J Mol Sci       Date:  2021-11-11       Impact factor: 5.923

4.  SignaLink 2 - a signaling pathway resource with multi-layered regulatory networks.

Authors:  Dávid Fazekas; Mihály Koltai; Dénes Türei; Dezső Módos; Máté Pálfy; Zoltán Dúl; Lilian Zsákai; Máté Szalay-Bekő; Katalin Lenti; Illés J Farkas; Tibor Vellai; Péter Csermely; Tamás Korcsmáros
Journal:  BMC Syst Biol       Date:  2013-01-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.